SBIR/STTR Research Award

TempO-LINC high throughput, high sensitivity single cell gene expression profiling assay

Award identifier 79b9987ab7082ea2d1ebf341d46cc6136dc3ce58e72c40079b6148b4721ccf70Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$402,266

Program and phase

SBIR · Phase I

Award year

2021

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Biospyder Technologies, Inc.
Proposal award date
2021-04-15
Contract end date
2022-03-31
UEI
KLCPP1J49GC5
Solicitation number
PA19-272
Topic code
400

Research abstract

Summary/Abstract: Single cell gene expression assays have become important tools to identify functional subtypes of cells, as well as changes within specific subtypes resulting from diseases or treatments. However, most current methods require dedicated hardware and kits, making them expensive, and most are 3’ based and thus cannot measure splice variants, gene fusions, expressed single nucleotide variants, or RNAs that are not polyadenylated. Furthermore, there is no method to-date that enables investigators to measure low or even many moderately expressed genes from single cells, which prevents measurements of many key biomarkers and important genes in molecular pathways and functions. Current methods also only measure a limited number of genes/cell and do not provide quantitative measurements of the abundance of those genes, and thus cannot be used to measure changes in expression level along the order of magnitude possible using bulk preparations of cells, nor can they be used to carry out dose response experiments at the single cell level. Our approach will enable investigators to carry out single cell assays without purchase of proprietary hardware, and provide a level of performance comparable to the profiling of bulk cell samples. Based on the commercial targeted gene expression TempO-Seq® bulk cell assay, we will implement a TempO-LINC single cell assay which, based on preliminary data, will provide data measuring the same genes (low, moderate, high expressed) and similar number of genes/cell as can be measured from bulk samples, quantitatively, providing a similar dynamic expression range and normal distribution of counts as measured from bulk samples. TempO-LINC can be used to process a few 100 single cells up to 100,000+ cells at a time. TempO-LINC data will be benchmarked against both bulk cell data and 10x Genomics single cell data. Furthermore, we will demonstrate utility to measure splice variants and to provide single cell dose response data. These data will be generated using the commercial S1500 surrogate whole transcriptome assay adapted to the TempO-LINC process. In a follow-on Phase II program, the human and mouse whole transcriptome assays will be implemented, the TempO-LINC assay commercialized, and additional applications demonstrated using cell lines, purified cells, and cells dissociated from tissues. The performance and capabilities of the TempO-LINC single cell assay will drive expansion of applications pursued within the single cell field beyond identification of subpopulations of cells.Project Narrative Singe cell gene expression assays have become important tools to identify functional subtypes of cells and changes in the numbers of cells within each subtype, or of subtypes, resulting from disease and treatments. However, current methods require dedicated hardware and kits, making them expensive, and do not permit low expressed genes that may be key biomarkers to be measured, typically only measuring a limited number of genes/cell, typically not providing quantitative measurements of abundance or changes in expression level, and are often 3’ based and so cannot measure splice variants or RNA such as long non-coding RNA that are not polyadenylated. We will demonstrate the feasibility of a novel TempO-LINC assay using a barcoding approach that does not require proprietary hardware, and demonstrate that this assay provides single cell data that measures the low and moderately expressed genes identified from bulk samples, is highly correlated to bulk cell benchmark assay data with respect to the number of genes/cell, represents the dynamic expression range of those genes within each cell, and can provide single cell dose response data - enabling single cell studies not previously possible to understand (e.g.) molecular mechanistic differences at the single cell level of disease, and drug efficacy and safety.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

26 SBIR/STTR records share this UEI (2013–2023). Reported award amounts total $19,935,581. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.